1. A clinical trial of treatment for lung disease in scleroderma fibrosing alveolitis in scleroderma (FAST study);Herrick;National Research Register (UK),2005
2. Hoyles R Ellis R Herrick A Foley N McHugh N Pearson S Fibrosing alveolitis in scleroderma trial (FAST): a multicentre prospective randomised double blind placebo controlled trial [Abstract] British Thoracic Society Winter Meeting; 2005 December 7-9; London 2005 ii48
3. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma;Hoyles;Arthritis and Rheumatism,2006
4. Clements PJ Tashkin D Roth M Khanna D Furst DE Tseng CH The scleroderma lung study II (SLS II) shows that both oral cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are efficacious in treating progressive interstitial lung disease (ILD) in patients with systemic sclerosis (SSC) American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting; 2015 November 6-11; San Francisco 2015
5. Patients with systemic sclerosis (SSC) enrolled in the scleroderma lung study (SLS) have a high mortality within 5 years of stopping Cyclophosphamide (CYC);Furst;Clinical and Experimental Rheumatology,2010